Globe Newswire 14-Jun-2018 6:14 PM
ANN ARBOR, Mich., June 14, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE:ZOM) (TSX-V:ZOM) ("Zomedica" or the "Company"), a veterinary diagnostic and pharmaceutical company, today announced the appointment of Michael Schilk as Vice President of Sales and David Eaton as Vice President of Marketing.
Michael Schilk joins Zomedica with more than 25 years of global sales and business development experience in both the human and animal health markets, including time at multiple Fortune 500 companies. Throughout his career, Schilk has been responsible for leading the commercial launch of pharmaceutical and diagnostic products across North America, Europe, Asia and Latin America and has held senior roles at Abbott Laboratories and Pfizer Inc., among others. He graduated with a Bachelor of Science degree in economics from the University of Arizona.
David Eaton brings more than 20 years of experience leading marketing organizations both in the US and internationally. Notably, he held senior marketing roles at animal health industry leader IDEXX Laboratories, Inc., where he was head of international strategy and marketing for the in-house diagnostics business and later held responsibility for integrated marketing for the $900 million US companion animal business. In addition, Eaton has held leadership roles at a number of private and public technology companies. He attended the University of South Carolina, where he was a member of the University's Honors College, and studied French, Music and Journalism.
Both Schilk and Eaton will report to Bruk Herbst, Zomedica's Chief Commercial Officer.
"We are excited to have Mike and David join our commercialization leadership team. Both bring rich experience from the animal and human healthcare industries," said Gerald Solensky, Jr., CEO, Zomedica. "They will be instrumental in bringing our ever-growing portfolio of diagnostics and therapeutics to market."
The Company also announced that Robert DiMarzo resigned as the Company's Executive Vice President of Global Strategy on June 12, 2018. Following that, Mr. DiMarzo has entered into a consulting agreement with Zomedica. Solensky continued, "We wish Robert well and look forward to continuing to consult with him on our commercial development strategy." DiMarzo added, I believe the Company is well positioned to capitalize on the opportunities available to it in the companion animal diagnostic and therapeutic markets, and I intend to remain available to consult on strategic issues as they may arise. I look forward to the Company's future success."
Based in Ann Arbor, Michigan, Zomedica (NYSE:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica's mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed in our filings with the Securities and Exchange Commission and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contacts
Shameze Rampertab, CPA, CA
PCG Advisory Group
Kirin Smith, COO
Limited Time Offer:
Claim your free copy of income expert Bryan Perry's new report:
My Top Monthly Dividend Payer (8% Dividend Yield)
You'll also receive Bryan Perry's weekly e-letter, Dividend Investing Weekly, at no cost, along with other associated financial content and special offers.